Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10ng/ml

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 3, 2006, Pages 235-238

  Kaygisiz, O ^a   Ugurlu O ^a   Kosan M ^a   Inal, G ^a   Ozturk B ^a   Cetinkaya M ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Antibacterial theraphy; Prostate biopsy; Prostate inflammation; Prostate specific antigen

Indexed keywords

ANTIINFECTIVE AGENT; CEFUROXIME AXETIL; CIPROFLOXACIN; OFLOXACIN; PROSTATE SPECIFIC ANTIGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DRUG EFFECT; HUMAN; HUMAN TISSUE; MALE; MASSAGE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATITIS; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; URINALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BIOPSY; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATITIS; RETROSPECTIVE STUDIES;

EID: 33748283141     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500885     Document Type: Review

References (23)

1. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol 1994; 151: 1571-1574.
2. Eskiçorapçi SY, Baydar DE, Akbal C, Sofikerim M, Gunay M, Ekici S et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444-449.
3. Schmid H-P, Prikler L, Sturgeon CM, Semjonow A. Diagnosis of prostate cancer - the clinical use of prostate specific antigen. EAU Update Ser 2003; 1: 3-8.
4. Neal Jr DE, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992; 20: 105-111.
5. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413.
6. Morote J, Lopez M, Encabo G, Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol 2000; 37: 537-540.
7. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: Correlation with prostate specific antigen value. J Urol 1997; 157: 1301-1304.
8. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002; 167: 1723-1726.
9. Karazanashvilii G, Managadze L. Prostate-specific antigen value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol 2001; 39: 538-543.
10. Carver BS, Caleb BB, Williams BJ, Venable DD. The prevalence of men with national institutes of health category IV prostatis and association with serum prostate specific antigen. J Urol 2003; 169: 589-591.
11. Reiter RE, deKernion JB. Epidemilogy, etiology, and prevention of prostate cancer. In: Walsh PC et al. (eds). Campell's Urology, vol. 4. Saunders: Philadelphia, 2002; pp 3003-3024.
12. Kwak C, Ku JH, Kim T, Park DW, Choi KY, Lee E et al. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer. Urology 2003; 62: 854-859.
13. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis. Eur Urol 1999; 37: 404-412.
14. Stancik I, Lüftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol 2004; 46: 760-764.
15. Ornstem DK, Smith DS, Humphrey PA, Catalona WJ. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998; 159: 1234-1237.
16. Jung K, Meyer A, Lein M, Rudolph B, Schnorr D, Loening SA. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 1998; 159: 1595-1598.
17. Bergman B. On the relevance of Gram-positive bacteria in prostatitis. Infection 1994; 22 (Suppl 1): 22.
18. Tanner MA, Shoskes DE, Shahed A, Pace NR. Prevalence of Corynebacterial 16S rRNA sequences in patients with bacterial and 'non-bacterial' prostatitis. J Clin Microbiol 1999; 37: 1863-1870.
19. Nickel JC. Prostatitis and related conditions. In: Walsh PC et al. (eds). Campell's Urology, vol. 1. Saunders: Philadelphia, 2002; pp 603-630.
20. Isaacs JT. Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Br J Urol 1993; 72: 918-921.
21. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: A randomized double-blind multicenter study. Urology 2003; 62: 537-541.
22. Witjes WP, Aarnink RG, Ezz-el-Din K, Wijkstra H, Debruyne EM, de la Rosette JJ. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 1997; 80: 84-90.
23. Potts JM. Prospective identification of national institutes of health category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000; 164: 1550-1553.